Psychiatric symptoms were improved more by second-generation antipsychotic drugs than by placebo in 421 outpatients with Alzheimer’s disease who had psychotic symptoms or agitation. For patients who completed 12 weeks of treatment with olanzapine, quetiapine, or risperidone, the proportions who were “much” or “very much” improved were 45%, 52%, and 61%, compared to 40% who were improved with placebo. Sultzer et al. (CME, p. 844) found that treatment effects in the Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) varied among the antipsychotics and specific symptoms. The effect on hostility—including anger, aggression, and paranoia—was most notable. None of the drugs, however, improved cognition, depression, functional abilities, care needs, or quality of life. Dr. Susan Schultz reviews these CATIE-AD results in an editorial on p. 787.